Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Multiple Sclerosis Drugs Market $25.3 Billion by 2027

The global market for multiple sclerosis drugs expected to attain $25.3 billion by 2027, steadily growing at a of CAGR 1.5% over forecast period, driven by large number of both existing therapeutics and new entrants in the marketplace.

  • Other market growth drivers include the anticipated launch of efficacious pipeline products that target the progressive MS subtypes, for patients with primary-progressive MS (PPMS) and secondary progressive MS (SPMS), as well as launch of oral therapies with improved convenience of administration over the current injectables.
Global Multiple Sclerosis Drugs Market

Multiple sclerosis (MS) is the most widespread disabling neurological condition of young adults around the world.

  • MS is more common among people in Europe, the United States, Canada, New Zealand, and sections of Australia and less common among people in Asia and the tropics.
    • The multiple sclerosis foundation estimates that more than 400,000 people in the United States and about 2.5 million people around the world have MS.
      • Although, an increasing number of people are being diagnosed with MS, there is increased awareness of MS and better diagnostic tools, such as magnetic resonance imaging (MRI), for diagnosing the disease.
        • MS is also an expensive disease to treat. direct and indirect healthcare costs range from $8,528 to $54,244 per patient per year in the United States.

Treatment for MS depends on the specific symptoms and may include: treating relapses of MS symptoms (with steroid medication), treating specific MS symptoms, and treatment to reduce the number of relapses (disease-modifying therapies).

  • Treatment options for relapsing-remitting MS include: Beta interferons are among the most commonly prescribed medications to treat MS and can reduce the frequency and severity of relapses.
    • Glatiramer acetate (Copaxone) may help block your immune system’s attack on myelin. Dimethyl fumarate (Tecfidera) can reduce relapses.
    • Fingolimod (Gilenya) and Teriflunomide (Aubagio) oral medications reduces relapse rate.
    • Natalizumab (Tysabri) blocks the movement of potentially damaging immune cells from your bloodstream to your brain and spinal cord.
    • Alemtuzumab (Lemtrada) drug helps reduce relapses of MS by targeting a protein on the surface of immune cells and depleting white blood cells.
  • In the past few years’ considerable improvements to slow MS disease progression has been made, as drugs such as fingolimod, dimethyl fumarate (Tecfidera), alemtuzumab (Lemtrada) and ocrelizumab have been launched.
Multiple Sclerosis-Clinical-Trials-Drugs

MS is highly heterogeneous, but has three main subtypes: relapsing forms of MS (RFMS), primary progressive MS (PPMS) and progressive relapsing MS (PRMS). RFMS can be further subdivided into relapsing remitting MS (RRMS) and secondary progressive MS (SPMS).

  • Currently, multiple sclerosis drugs in active development (clinical phase II and III pipeline) includes ARGX-113, GNbAC1, IB-MS, Imilecleucel-T, M2951, MIS416, Ofatumumab, Opicinumab, Ozanimod, Ponesimod, Siponimod, and Ublituximab.

The global MS treatment market report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global multiple sclerosis treatment market segmented by product (brand) [alemtuzumab (Lemtrada), dimethyl fumarate (Tecifidera), gilneya (Fingolimod), glatiramer acetate (Copaxone), interferon-β1a (Avonex), interferon-β1a (Rebif), interferon-β1b (Betaseron/Extavia), natalizumab (Tysabri), peginterferon-β1a (Plegridy), teriflunomide (Aubagio)], by clinical pipeline (phase III) – daclizumab (Zinbryta), ocrelizumab (Ocrevus), ozanimod (RPC-1063) and geography.

  • The MS therapeutics market is entering a crucial stage, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action.
    • The introduction of more effective and less invasive therapies expected to drive growth in the next few years.
    • The arrival of novel oral disease-modifying therapies (DMTs) fulfills a significant unmet need in the treatment of MS by providing patients with a more convenient route of administration.
  • The current MS pipeline is very robust, with numerous promising DMTs set to enter the market during the coming years.

Because of the low level of competition, existing market players have periodically increased prices. However, this trend is expected to change as a result of growing pressure from payers and launches of new agents and biosimilars.

  • In the long term, however, market growth will be offset by biosimilar incursion, which will create heightened cost competition over the forecast period.
    • With spiraling health-care expenditure, the scope for cost savings by switching away from the expensive MS drugs to the cheaper biosimilars will become key resistors causing the market to decline and plateau.

The global market for multiple sclerosis treatment research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

The global MS drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

  • As the MS market becomes saturated in the next 10 years, drug developers will need to look at alternative ways to grow the market.
    • Currently, most existing and pipeline treatments only work for the relapse-remitting form of MS, which accounts for around 55% of the patient population.
      • The greatest unmet need is for effective treatments for the remaining 45% of patients who suffer from the more severe progressive forms of MS.

Major competitors operating in the global multiple sclerosis drugs market and included in this report are Actelion Pharmaceuticals Ltd., arGEN-x SE, Bayer AG, Biogen, Inc., Celgene Corporation, GeNeuro SA, Innate Immunotherapeutics Ltd., Inno Bioscience LLC, Merck & Co., Inc., Novartis AG, Opexa Therapeutics, Inc., Pfizer, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and TG Therapeutics, Inc.

  • Product (Brand)
    • Alemtuzumab (Lemtrada)
    • Dimethyl Fumarate (Tecifidera)
    • Gilneya (Fingolimod)
    • Glatiramer Acetate (Copaxone)
    • Interferon-β1a (Avonex)
    • Interferon-β1a (Rebif)
    • Interferon-β1b (Betaseron/Extavia)
    • Natalizumab (Tysabri)
    • Peginterferon-β1a (Plegridy)
    • Teriflunomide (Aubagio)
  • Clinical Pipeline (Phase III)
    • Daclizumab (Zinbryta)
    • Ocrelizumab (Ocrevus)
    • Ozanimod (RPC-1063)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU),
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Actelion Pharmaceuticals Ltd.
    • arGEN-x SE
    • Bayer AG
    • Biogen, Inc.
    • Celgene Corporation
    • GeNeuro SA
    • Innate Immunotherapeutics Ltd.
    • Inno Bioscience LLC
    • Merck & Co., Inc.
    • Novartis AG
    • Opexa Therapeutics, Inc.
    • Pfizer, Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • TG Therapeutics, Inc.

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]